Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC
AimsThis study aims to determine differences in severity of background liver disease at hepatocellular carcinoma (HCC) diagnosis and long-term survival outcomes among patients undergoing liver resection for HCC in the background of metabolic dysfunction-associated fatty liver disease (MAFLD) compare...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.783339/full |
| _version_ | 1818744501126037504 |
|---|---|
| author | Lei Liu Si Xie Yu-Xian Teng Zhu-Jian Deng Kang Chen Hao-Tian Liu Rong-Rui Huo Xiu-Mei Liang Ping-Ping Guo Da-Long Yang Liang Ma Bang-De Xiang Le-Qun Li Jian-Hong Zhong |
| author_facet | Lei Liu Si Xie Yu-Xian Teng Zhu-Jian Deng Kang Chen Hao-Tian Liu Rong-Rui Huo Xiu-Mei Liang Ping-Ping Guo Da-Long Yang Liang Ma Bang-De Xiang Le-Qun Li Jian-Hong Zhong |
| author_sort | Lei Liu |
| collection | DOAJ |
| description | AimsThis study aims to determine differences in severity of background liver disease at hepatocellular carcinoma (HCC) diagnosis and long-term survival outcomes among patients undergoing liver resection for HCC in the background of metabolic dysfunction-associated fatty liver disease (MAFLD) compared to chronic hepatitis B (CHB) alone or concurrent CHB (CHB/MAFLD).MethodsPatient demographics and comorbidities, clinicopathologic data, perioperative and long-term outcomes among patients who underwent liver resection for HCC were reviewed. Overall and recurrence-free survival were calculated with the Kaplan-Meier method, with the values compared using the log-rank test.ResultsFrom January 2014 to December 2018, 1325 patients underwent potential curative liver resection of HCC; 67 (5.0%), 176 (13.3%), and 1082 (81.7%) patients had MAFLD alone, CHB concurrent with MAFLD, and CHB alone, respectively. At HCC diagnosis, fewer MAFLD patients had cirrhosis, alpha fetoprotein concentration ≥ 400 ng/mL, tumor size ≥ 5 cm, mulinodular, microvascular invasion, receiving major hepatectomy, and receiving adjuvant transarterial chemoembolization. After a median follow-up of 47 months after liver resection, MAFLD (or MAFLD plus CHB/MAFLD) patients had significantly higher overall and recurrence-free survival than CHB patients before or after propensity score analysis (all P<0.05).ConclusionPatients with HCC in the setting of MAFLD have less-severe background liver disease at HCC diagnosis and better long-term survival after curative liver resection compared to counterparts with CHB/MAFLD or CHB. |
| first_indexed | 2024-12-18T02:45:18Z |
| format | Article |
| id | doaj.art-dd2f4f63ab9a436aaf58ac1edde8a490 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-18T02:45:18Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dd2f4f63ab9a436aaf58ac1edde8a4902022-12-21T21:23:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.783339783339Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCCLei Liu0Si Xie1Yu-Xian Teng2Zhu-Jian Deng3Kang Chen4Hao-Tian Liu5Rong-Rui Huo6Xiu-Mei Liang7Ping-Ping Guo8Da-Long Yang9Liang Ma10Bang-De Xiang11Le-Qun Li12Jian-Hong Zhong13Hepatobiliary Surgery Department, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou Workers Hospital, Liuzhou, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, ChinaAimsThis study aims to determine differences in severity of background liver disease at hepatocellular carcinoma (HCC) diagnosis and long-term survival outcomes among patients undergoing liver resection for HCC in the background of metabolic dysfunction-associated fatty liver disease (MAFLD) compared to chronic hepatitis B (CHB) alone or concurrent CHB (CHB/MAFLD).MethodsPatient demographics and comorbidities, clinicopathologic data, perioperative and long-term outcomes among patients who underwent liver resection for HCC were reviewed. Overall and recurrence-free survival were calculated with the Kaplan-Meier method, with the values compared using the log-rank test.ResultsFrom January 2014 to December 2018, 1325 patients underwent potential curative liver resection of HCC; 67 (5.0%), 176 (13.3%), and 1082 (81.7%) patients had MAFLD alone, CHB concurrent with MAFLD, and CHB alone, respectively. At HCC diagnosis, fewer MAFLD patients had cirrhosis, alpha fetoprotein concentration ≥ 400 ng/mL, tumor size ≥ 5 cm, mulinodular, microvascular invasion, receiving major hepatectomy, and receiving adjuvant transarterial chemoembolization. After a median follow-up of 47 months after liver resection, MAFLD (or MAFLD plus CHB/MAFLD) patients had significantly higher overall and recurrence-free survival than CHB patients before or after propensity score analysis (all P<0.05).ConclusionPatients with HCC in the setting of MAFLD have less-severe background liver disease at HCC diagnosis and better long-term survival after curative liver resection compared to counterparts with CHB/MAFLD or CHB.https://www.frontiersin.org/articles/10.3389/fonc.2021.783339/fullchronic hepatitis Bhepatocellular carcinoma (HCC)liver resectionmetabolic dysfunction-associated fatty liver diseaseoverall survival |
| spellingShingle | Lei Liu Si Xie Yu-Xian Teng Zhu-Jian Deng Kang Chen Hao-Tian Liu Rong-Rui Huo Xiu-Mei Liang Ping-Ping Guo Da-Long Yang Liang Ma Bang-De Xiang Le-Qun Li Jian-Hong Zhong Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC Frontiers in Oncology chronic hepatitis B hepatocellular carcinoma (HCC) liver resection metabolic dysfunction-associated fatty liver disease overall survival |
| title | Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC |
| title_full | Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC |
| title_fullStr | Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC |
| title_full_unstemmed | Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC |
| title_short | Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC |
| title_sort | outcomes of liver resection for metabolic dysfunction associated fatty liver disease or chronic hepatitis b related hcc |
| topic | chronic hepatitis B hepatocellular carcinoma (HCC) liver resection metabolic dysfunction-associated fatty liver disease overall survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.783339/full |
| work_keys_str_mv | AT leiliu outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT sixie outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT yuxianteng outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT zhujiandeng outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT kangchen outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT haotianliu outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT rongruihuo outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT xiumeiliang outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT pingpingguo outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT dalongyang outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT liangma outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT bangdexiang outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT lequnli outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc AT jianhongzhong outcomesofliverresectionformetabolicdysfunctionassociatedfattyliverdiseaseorchronichepatitisbrelatedhcc |